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Factor X activation
Abstract. A chromogenic factor IX assay is developed which requires only two time-
dependent steps. Diluted plasma is mixed with a reagent containing factors VIII and X. The
reaction is started by addition of a reagent containing factor XI", thrombin, CaCl2, and
phospholipids. Then factor XIu activates factor IX if present, thrombin activates factor VIII,
and subsequently the complete factor X activating complex (factor IXu, factor VIII1, Ca ions,
and phospholipids) rapidly activates factor X. Finally, ethylenediaminetetraacetic acid plus
a chromogenic substrate are added to stop the reaction and to measure formed factor Xu.
Factor X" formation is proportional to the plasma factor IX concentration (from 0 to 1400/o).
The two reagents needed for the assay are stable at room temperature during a whole working
day and for 3 h at 37 'C. A new isolation procedure for factor VIII is described. Factor VIII is
purified from bovine plasma in a few steps with a yield of 20o/o and a 8,000-fold purifrca-
tion.
Introduction
Factor IX (Christmas factor) is an impor-
tant zymogen of the blood coagulation. Defi-
ciency of this protein in blood leads to bleed-
ing problems: hemophilia B [see ref. I for a
reviewl. Factor IX is a vitamin K dependent
protein and thus contains 1-carboxyglutamic
acid residues. These 1-carboxyglutamic acid
residues are possibly involved in the binding
of factor IX (and also other vitamin K de-
pendent clotting factors) to negatively
charged phospholipid membranes via calci-
um bridges [2]. Human factor IX is a glyco-
protein \,\rith a carbohydrate content of about
l7o/o and with an apparent molecular weight
of 57,000 [3, 4]. The plasma concentration is
46-88 nM. Factor IX can be activated by fac-
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tor XI" and by the factor Vllu-tissue factor
complex. Both enzymes cleave the same
bonds in factor IX which results in a two-
chain factor IXup and an activation peptide
(Mr :  11 ,000) .
Factor IX" is an important enzyme of the
intrinsic pathway of blood coagulation [for
reviews see refs. 5 and 6]. Factor IXu acti-
vates factor X in a reaction that is acceler-
ated enormously by factor VIII., phospholip-
ids, and calcium ions [7]. Several methods
are described to measure factor IXu: a clot-
ting assay using factor IX deficient plasma
[8], a method based on the esterase activity
of factor IXu using radiolabeled esters [9], a
method to determine the release of the tri-
tiated activation peptide which originally
was described by Silverberg et al. [10], an
immunoradiometric assay [1], a spectro-
metric assay described by Tans et al. [12],
and an active-site titration with p-nitro-
phenyl-p-guanidino benzoate hydrochloride
[13]. All these methods (except the clotting
assay which, however, is not very precise)
have the disadvantage ofbeing laborious and
thus are unsuited for a routine determina-
tion in a clinical laboratory.
In order to measure factor IX quantita-
tively, (l) it has to be activated, and (2) the
formed factor IXu should activate factor X
under conditions that factor IXu is the rate-
limiting compound. In this paper we
searched for oitimal reaction conditions and
a procedure to minimize the incubation time
and the pipetting steps. For a chromogenic
factor IX assay we do not need a 1000/o pure
factor VIII; however, the preparation should
not contain fibrinogen or other components
that interfere with the assay. In this paper we
describe the isolation of bovine factor VIII
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Materials and Methods
Materials
FXu substrate (CH3OCO-D-CHG-GIy-Arg-pNA-
AcOH) and o-NAPAP [N-o-(2-naphthylsulfonylgly-
cyl)-D,t-amidinophenyl-alanrne-piperidide hydroid-
idel were obtained from Pentapharm (Switzerland);
Sph6rosil X 015 LS was from Rhdne Poulenc
(France); Sephadex G-25 f ine was from Pharmacia
(Sweden); immunoadsorbed factor IX deficient plas-
ma was donated by Baxter Dade (Switzerland); S2337
IN-benzoyl-t-isoleucyl-Z- glutamyl-(prperidyl)-I-gly-
cyl-l-arginine-p-nitroanilide hydrochloridel, S2238
(H - D - phenylalanyl - I - pipecolyl - -L - arginine -p - nitro-
anilide dihydrochloride) and RVV-X (factor X acti-
vator from Russell's viper venom) were from Kabi
(Sweden).
All other reagents were of the highest grade com-
mercially available
Phospholipids and Phospholipid Vesicles
Phosphatidylcholine was extracted from egg yolks
according to the method of Bligh and Dyer [1 4] and
purifred as described by Comfurius and Zwaal [15].
Phosphatidylserine was prepared in a similar way,
however, extracted from bovine brains. Vesicles were
prepared by sonication ofa phospholipid mixture in a
buffer containing 50m-M Tris-HCl and l75mM
NaCl (pH 7.9) using an MSE Mark II 150-watt ultra-
sonic disintegrator set at 9 p peak-to-peak amplitude.
The composition of the vesicles was 75 molO/o phos-
phatidylcholine and 25 molo/o phosphatidylserine or
as indicated.
Proteins
All proteins were isolaled from bovine plasma.
Factor X was isolated according to the method of
Fujikawa et al. [16]. Human factor IX [see refs. 17
and 18] was a gift ofT. Janssen-Claessen Factor IXo
was prepared by activating human factor IX with iso-
lated factor XIu according to the method of Fujikawa
et al. [19]. Bovine factor XIu (contact product) was
isolated as described by Nossel [20] and Osterud and
Rapaport [21]. Prothrombin was isolated accordtng
to the method of Owen et at. [22]. Thrombin was pre-
pared from prothrombin by activatron with pro-
thrombinase as described elsewhere [23].
Eastqr YIII was lqeasurq4 asqesegbed bv Yaeq!-
Factor VI(I was measured as described by Wagen-
voord et al. [24]. As reference plasma normal pooled
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healthy donors; the plasma was donated by T. Jans-
sen-Claessen. The reference plasma was compared a
few times with the reference plasma provided by
Baxter (CoagCal). Both plasmas contained the same
amount of factor VIII; differences of less than 30lo
were found. By definition, normal pooled plasma
contains I U/ml factor VIII.
To measure factor Xu formation in time, samples
ofthe reaction mixture were added to a cuvette con-
taining 20 m-7l1 ethylenediaminetetraacetic acid in
standard buffer (see below). The final volume after
subsampling was 980 pl. Factor Xu then was mea-
sured by addition of 20 pl of 4 mM FXu substrate
plus 50 pM o-NAPAP to the cuvette [see ref. 24].
o-NAPAP was added to the FX" substrate to inhibit
hydrolysis ofthis chromogenic substrate by thrombin.
I pM o-NAPAP inhibits thrombin by 99.50/o 1241.
Reaction Conditions
All reactions were done at 37 " C: in each case the
reagents were preincubated at 37 " C during 5 min. All
proteins were dissolved in 175 mtr1NaCl and 50 mM
Tris-HCl (standard buffer). All dilutions were done in
the same buffer containing 0.5 mg/ml ovalbumin.
Results
Isolation of Factor VIII
Bovine blood was collected in l0-liter
vessels containing I liter 100 mMbenzami-
dine, 100 m-41sodium citrate, 20 U/ml hepa-
rin, and 100 mg/l soybean trypsin inhibitor.
The next steps were done at 0-4'C. The
blood was centrifuged at 5,0009 during 15
min. The plasma was collected and to the
plasma was added polyethylene glycol
20,000 (1.80/0, wiv). The mixture was stirred
during 10 min, and then the formed precipi-
tation was spun down at 2,000S: (10 min).
The precipitate was dissolved in 120 mM
NaCl and l0 mM trisodium citrate (frnal
volume about one twentieth of the plasma
volume). To the solution was added 50 mM
B-mercaptoethanol, and the mixture was in-
cubated during the night at 0'C. Next day
the formed precipitation was spun down at
5,000 g during 30 min. The supernatant
usually was frozen at -80'C until further
use.
A few factor VIII preparations were
thawed and combined. To the preparation
was added Sphdrosil PL (4 g/l). Sphdrosil PL
was prepared by addition of 5 0/o (w/w) phos-
pholipids dissolved in chloroform (10 mgl
ml) to Sphdrosil (X 015 LS). The phospho-
lipid composition was 95 molo/o phosphati-
dylcholine and 5 molo/o phosphatidylserine.
The chloroform was evaporated in vacuum
until dryness. Then the Sphdrosil PL was
washed with isotonic salt. The factor VIII
preparation was stirred during the night with
the Sph6rosil PL at room temperature. Next
day the Sphdrosil PL was collected and
poured into a small column (5 cm2). The
Sphdrosii PL was washed very carefully with
isotonic salt. Factor VIII was eluted from
Sphdrosil PL with I M sodium thiocyanate
and I M NaCl (pH 6.2). The eluted factor
VIII was gel frltrated immediately to remove
the salt by elution on a Sephadex G-25 col-
umn (50 X 5 cm3) which was equilibrated
with 175mM NaCl and 50m-41 Tris-HCl
(pH 7.9). The activity of factor VIII varied
from 100 to 250 U/ml. The optical density at
280 nm ofthe preparations was about l. The
obtained preparation did not promote plate-
Iet aggregation, so it is free of active von Wil-
lebrand factor.
Properties of Factor VIII
We have determined the amount of
thrombin that is needed for complete activa-
tion of factor VIII. In figure I the result of
this experiment is shown. One can observe
that remarkably high concentrations of
thrombin (more than 100 nM) are necessary
to activate factor VIII completely.
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The amount of activated factor VIII nec-
essary for complete saturation of the factor
IXu was determined in a similar way as
described by Van Dieijen et al. [25]. In a
mixture containing human factor IXu,
CaCl2, phospholipid vesicles, thrombin, and
factor X, the factor VIII concentration was
varied (1.25-10 U/ml). In this reaction mix-
ture, the factor X activating reaction was
linear, with the reaction time between 15
and 90 s. The reaction rates were plotted
double reciprocally against the factor VIII
concentrations, obtaining straight lines from
which the kinetic constants of the reaction
were calculated. The V-u* is 4.256 nMlmin,
and the turnover number is 851 (moles fac-
tor X" formed per minute per mole factor
IXu). To obtain a half maximal reaction rate,
3.64U/ml factor VIII is required. This
means that very high factor VIII concentra-
tions are necessary to saturate the factor X
activating complex almost completely. For a
900/o saturation, already 32.8 U/ml factor
VIII is required. By increasing the final
CaClz concentration to l3.4mM, the Y^u*
was hardly changed (792); however, the
amount of factor VIII necessary for a half
maximal rate increased tenfold (32.8 U/ml).
This means that by increasing the CaCl2 con-
centration, the affinity of factor VIII. to the
factor X activating complex decreases. So it
is possible to modulate the reaction rate by
changing the CaCl2 concentration.
In the same way as described by Van
Dieijen et al. [25] we have determined the
molar concentration of 1 U/ml factor VIII.
At a very low factor VIII concentration
(l/120 U/ml), the assay was saturated with
excess of factor IXu. We found that the dis-
sociation constant of factor IXu for the factor
X activating complex was 17.3 nM, and the
maximal rate of factor X. formation was
Fig. 1. Activation of factor VIII as a function of
the thrombin concentration. Factor VIII (5 U/ml) was
activated with thrombin during 15 s in the presence
of 5 m.4,1 CaCl2. Forty microliters of the activated fac-
tor VIII was added to 160 pl of 1.25 pM factor X,
25 1tM phospholipid vesicles, 5 rnM CaClz, and
25 nM factor IXu. Samples of 20 pl were taken at 20
and 40 s reaction time, and the factor Xu formation
was measured.
4.88 nMlmin. From these data we have cal-
culated that I U/ml factor VIII equals
0.688nM, assuming that factors VIII. and
IXu are present in the factor X activating
complex at equimolar amounts [25].
The results described above have shown
that for practical reasons it is not possible to
work with saturating amounts of factor VIII;
this means that the rate of factor Xu forma-
tion depends on the factor VIII concentra-
tion in the reaction mixture. For that reason
we have studied the stability of the factor
VIII at 37 "C. Figure 2 shows that factor
VIII is not stable in the absence of CaClz;
however, when 0.1 mM CaCl2 is present, fac-
tor VIII is stable. The activity in the absence
250
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a
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Fig.2. Stability of diluted factor VIII at 37"C.
Factor VIII was diluted to about l 7 U/ml in standard
buffer containing 2.0 mg/ml ovalbumin and no (o),
25 1tM (t), or 100 trtM (r) CaCI2.
Fig. 3. Activation of human factor IX with factor
XIu. To 100 pl 400 nM thrombin, 80 pM phospho-
lipid vesicles, and 15 mM CaCl2 was added 100 pl
factor XIu of 0, l, 2, 3, 4, 5, and 6nM. At t : 0 min
100 pl human factor IX (50 pM) was added and at t:
2 min 100 pl of a mixture containing 2.5 U/ml factor
Ylll, I pM factor X, and 5 mM CaCl2. At t : 4 min
samples of 200 pl were taken, and the formed factor
Xu was measured. To correct for hydrolysis of FXu
substrate by factor XIu, the same experiment was
done without factor X.
of CaCl2 dropped by 680/o after lOh at
37"C, whereas in the presence of O.lmM
CaCl2 the activity dropped by only 20010. So,
by addition of 0.1mM CaClz to the reagent
with factor VIII, it is sufficiently stable to
use in the chromogenic factor IX assay.
Optimization of the Factor IX Assay
We have determined the optimal concen-
trations of factor XIu, phospholipid vesicles,
and factor X for a well-working chromogenic
factor IX assay.
In figure 3 we have determined the con-
centration of factor XIa that is necessary to
activate human factor IX completely within
2 min. This concentration is about 1.0 nM.
The dependency ofthe assay on phospho-
lipid concentration and composition is very
similar as described by Van Dieijen et al. [7]
and Wagenvoord et al. 1241. For that reason
only the results of these studies are given.
The reaction rate is maximal at a phospho-
lipid concentration of I pM (25 molo/o phos-
phatidylserine, 7 5 molo/o phosphatidylchol-
ine). At higher concentrations the activity
slowly decreases, and at lower concentration
it sharply drops to almost zero in the absence
of phospholipids. We have also studied
whether changing the composition of the
phospholipids affects the reaction rate. Ad-
dition of cholesterol or phosphatidylethanol-
amine to the vesicles did not lead to higher
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activating complex was different, it was
composed of bovine factor IXu and human
factor VIII".
The results described above have shown
that an optimal factor IX assay is obtained
when the factor XI^ concentration is 1 n,ll4
during factor IX activation, the thrombin
concentration during factor VIII activation
is 100 nM or more, and the final factor X
concentration is far above the K- (300 nM).
We decided to use 20 pM phospholipids be-
cause at this concentration the reaction is
not very much dependent on the phospho-
lipid concentration.
It was shown that very high factor VIII
concentrations are required to bind all factor
IXu in the factor X activating complex. For
practical reasons it is not possible to use such
high amounts of factor VIII on large scale.
For that reason we have investigated
whether the formed factor Xu is linearly de-
pendent on the factor IX concentration un-
der conditions that factor VIII is not saturat-
mg.
Properties ofthe Factor IX Assay
To minimize pipetting steps we have pre-
pared two reagents with compositions based
on the above-described results. Reagent I
contained 300 nM thrombin, 15 mM CaCl2,
2 nM factor XIu, and 60 ttM phospholipid
vesicles. Reagent 2 contained I pM factor X,
3 U/ml factor VIII, and 0.1 mM CaClz. The
CaClz in reagent 2 is added to stabilize the
factor VIII. The generally used pipetting se-
quence was: at t : 0 min 100 pl of reagent I
was mixed with 100 pl diluted plasma, at t:
2 min 100 pl of reagent 2 was added, and at
t : 4 min samples of 100 pl were taken to
measure formed factor X".
Figure 4 shows that the assay is linear
with the percentage factor IX in the plasma
Fig.4. Factor IX assay of plasmas with variable
amounts of factor IX. Immunoadsorbed factor IX
deficient plasma was 200 times diluted in standard
buffer (0 0/o factor IX), normal pooled plasma was 200
times diluted ( 100 0/o factor IX) and 100 times diluted
(2000/o plasma) in the same buffer. By mixing the
diluted plasmas, we prepared plasmas with 0-2000/0
factor IX. The pipetting sequence was: at t : 0 min
100 pl reagent 1 (300 n:tr' thrombin, 15 rnM CaClz,
2nM factor XI,, 60pM phospholipid) was mixed
with 100 pl diluted plasma; at t : 2 min 100 pl
reagent 2 (l pM factor X, 3 U/ml factor VIII, O.l mM
CaClz) was added, and at t:4 min samples of 100 pl
were taken to measure formed factor Xu.
reaction rates, and changing the ratio be-
tween phosphatidylcholine and phosphati-
dylserine from l0 to 2 in the vesicles did not
lead to higher activities.
In a similar way as described by Wagen-
voord et al.1241, the K- of factor X activa-
tion by the complete factor X activating
complex was determined. The K- is 45 nM.
The K- is comparable with that found in the
case of factor VIII assay [24]. Although in
that case the composition of the factor X
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Table l. Stability of the factor IX assay reagents
Incubation Activity
Table 2. Determination of factor IX in plasmas of
patients treated chronically with oral anticoagulants
Plasma Factor IX in plasma, o/o
time, h temperature
' c
factor Xu
nMlmin
o/o
chromogenic
factor IX
assay
APTT method
22
22
22
0
A
24
27.3
25.9
25.2
100
94.9
92.6
5
trmes
l 0  100
times times
0
1
J
37
37
37
27.3
26.9
25.7
1
2
J
A
5
6
7
8
9
1 0
1 1
t 2
1 3
t 4
1 5
16
24.6
23.3
25.5
22.9
100
98.5
94.4
t4.6
13 .8
r3.6
12 .3
19.2
23.4
20.6
15 .0
9.5
12 .9
14.6
r7 .6
a A  1
1  1 . 6
26.6
16 .3
2r .8  r2 .8
20.5 11.5
2 l .8  l l . 7
20.2 11.3
30.3 15.9
29.4 r7.4
27.r  14.6
20.0 12.8
15 .8  7 .3
t7.5 '7 .4
21.4 10.5
27. t  14.2
3s.4 18.3
20.2 11.3
32.9 r'7.'.7
26.9 15.4
Method and composition of the reagents I and 2
are described in text. At the indicated incubation
time, a fresh plasma dilution was made (normal
pooled plasma, 200 times diluted).
lupto2000/o, although the factor VIII concen-
tration is I U/ml which is below the fu.
Because we use nonsaturating factor VIII
concentrations in the factor IX assay, the
assay is sensitive for inactivation of factor
VIIL The other clotting factors are present in
excess, so changes in their concentration
would not affect the reaction rate very much.
We have prepared the reagents 1 and 2 and
tested whether they are stable at 3'7 " C and at
room temperature. In table I the results of
these tests are shown. One can notice that
even after 3hat37'C or after 24hat22"C
(ambient temperature) the assay is stable
within 7.40l0.
Factor IX Detection in Different Plasmas
with Modified Reagents
For clinical application of the chromo-
genic factor IX assay, plasma dilutions of I in
200 are not practical. In clinics one would
like to dilute the plasma in one step. Plasma
dilutions of I in 31 or 1 in 41 are more suit-
Factor IX was measured in two ways: either using
the modifred chromogenic factor IX assay described
in frgure 5b or the standard APTT method using fac-
tor IX defrcient plasma; as 1000/o we used either five
tirnes, ten times, or 20 times diluted reference plasma
(CoagCal, Baxter). In the last case the plasma samples
were diluted 100 times, and corrections were made to
account for the additional dilution.
able. However, the reaction rate would be far
too high when the reaction conditions shown
in figure 4 are used. As was described aboye,
the reaction rate can be decreased by increas-
ing the CaClz concentration of the reaction
mixture. The reaction rates can be decreased
also by addition of smaller plasma volumes
to the reaction mixture. For those reasons we
prepared modifred reagents I and 2 and
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Fig.5. Standard curves for the chromogenic factor
IX assay. Two modified reagents were prepared. The
modified reagent I contained 225 nM thrombin,
45pM phospholipid vesicles, 3OmM CaClz, and
I.25nM factor XIu. The modifred reagent 2 con-
tained 1.5 U/ml factor VIII, 750 nM factor X, and
0.1 mM CaClz. Normal pooled plasma was diluted in
isotonic salt 31, 41, 82, and 164 times. For the blank
isotonic salt was used. The plasma dilution I in 41 is
called 100 0/0. a The pipetting scheme was: at t : 0 min
100 pl reagent I was mixed with 25 pl diluted plasma,
and at t: 3 min 100 pl reagent 2 was added. At t = 4.5
min 500 pl stop buffer (i.e.,20 mM ethylenediamine-
tetraacetic acid, 128 pM FXu substrate, 1.6 1tM u'
NAPAP) was added, and factor Xu formation was
immediately measured. The final CaCl2 concentra-
tion in the reaction mixture was 13.4 mM. b 100 pl
reagent 2 was mixed with 25 pl diluted plasma. At t:
0 min 100 pl reagent 1 was added to start the reaction.
After 3 min the reaction was terminated by addition
of 500 pl stop buffer, and the formed factor Xu was
immediately measured.
changed the pipetting sequence somewhat
(see legend to figure 5). By having present
FXu substrate in the stop buffer, factor Xu
was measured immediately, and one subsam-
pling step was avoided. By mixing reagent 2
with the diluted plasma, starting the reaction
with reagent 1 and terminating the reaction
after 3 min by addition of stop buffer, the
procedure was simplified even more.
Figure 5a shows a reference curve of fac-
tor IX determinations in human plasma with
the modifred chromogenic factor IX assay.
Normal pooled plasma was diluted as indi-
cated. A dilution of I in 4l is called 1000/o
factor IX. One can observe that also in this
case a linear relationship exists between the
percentage factor IX and the factor Xu for-
mation. The blank value is higher than in
figure 4 because the whole reaction mixture
is used. The blank is caused by hydrolysis of
the chromogenic substrate by factor XIu. In
figure 5b the reference curve is shown for the
most simplified procedure, i.e., starting the
reaction with reagent 1. Also in this case the
percentage factor IX is proportional with the
factor Xu formation.
Using the method described in the legend
to figure 5, we have measured factor IX in
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plasmas of patients who were chronically
treated with oral anticoagulants. Firstly, a
reference curve was prepared, and then the
patient plasmas were diluted 41 times in iso-
tonic salt and the factor IX measured as
described. The factor IX was also measured
according to the standard activated partial
thromboplastin time (APTT) method using
factor IX deficient plasma. In table 2 the
results of these tests are shown. It is noticed
that the results obtained with the APTT-
based assay are dependent on the plasma
dilution. A possible reason for this finding is
discussed later. At a high plasma dilution
there is a reasonable good correlation be-
tween the APTT-based assay and the chro-
mogenic factor IX assay.
We also have investigated stability and
activity of the modified reagents after lyo-
philization. Modifred reagents 1 and 2 were
prepared, divided in 2-ml amounts, and ly-
ophilized. Their activity was tested before
and after lyophilization. Before lyophiliza-
tion with a plasma dilution of I in 41 and
isotonic salt (blank), the formed amounts of
factor Xu were 13.76 and 0.97 nM, respec-
tively. After lyophilization, these values
were 13.74 and l.25nM. After 6 months,
these levels were not decreased: 13.99 and
1.08 nM, respectively.
The sensitivity of the assay is determined
in plasma. In ten determinations in reference
plasma we found 14.15 + 0.419 nMlmin,
whereas for 24 blank determinations values
of 0.545 + 0.053 nMlmin were found. A
variation of about 100/o is found for the
blank. A lo/o plasma gives a rate of
0.136 nMlmin in addition to the blank
which is 2.5 times the standard deviation. So
it is well possible to measure an amount of
10/o plasma; however, to be precise, the mea-
surement must be repeated a few times.
A freld trial was performed with lyophi-
lized reagents [26]. In this study were inves-
tigated healthy subjects, patients receiving
oral anticoagulants and heparin, and various
diseases, namely mild and serrere hemophilia
A and B, von Willebrand's disease, lupus-
like anticoagulant, and others.
Our study has shown that (1) the correla-
tion between the APTT-based clotting assay
and the chromogenic assay is very well; (2)
the average for normal plasma (n : 40) is
95.4 + 14.0o/o; (3) for a patient with mild
hemophilia B with the APTT-based assay
130/o was found and 110/o with the chromo-
genic assay - in case of severe hemophilia B
with both assays less than l0lo was found; (4)
in cases of mild and severe hemophilia A
with both assays similar results were found:
90 and 93o/o, 66.5 and 620/o,50 and 56.50/o,
and 62 and 72o/o, respectively - also in case
of von Willebrand's disease the results were
similar: 80 and 84 and 74 and 800/0, respec-
tively, and (5) tests with factor IX concen-
trate showed a good correlation: with the
APTT-based assay were found 20.9, 21.0,
and 26.7 U/ml and with the chromogenic
assay 23.1, 19.6, and 25.6U/ml.
Discussion
In this paper we have described the devel-
opment of a chromogenic factor IX assay
that is well suited for clinical use. Tans et al.
[2] already described a spectrophotometric
assay for human plasma factor IX. The main
difference between the assay described by
Tans et al. |21and our assay is the use of
isolated purifred factor VIII. For that reason
the assay described by these authors requires
a much longer time to activate an apprecia-
ble amount of factor X. Another difference
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between both assays is the time needed for
factor IX activation. Tans et al. [12] use a
separate preactivation step of 25 min,
whereas in our case factor XI is activated in
the final mixture within a few minutes. This
shows that in spite of the accuracy, the
method of Tans et al. [2] is not suitable for
clinical use, because the procedure takes a
long time, and a number of pipetting steps
are necessary. The procedure described in
this article is simple and requires only two
pipetting steps at fixed times. The reagents
necessary for the assay can be kept at room
temperature during a whole working day
without loosing their activity. Because of the
simplicity of the method, it is well possible
to automate the whole procedure. The lyoph-
ilized reagents ready for use can be obtained
from Baxter.
Because we need large amounts of puri-
fied factor VIII for the factor IX assay, it was
necessary to develop a new isolation proce-
dure for bovine factor VIIL The kinetic
properties of this factor VIII are comparable
with those described for bovine facor VIII
[25] which was isolated in a different way
1271. The removal of von Willebrand factor
from the preparation can occur during two
steps in the isolation procedure. During re-
duction of the preparation, von Willebrand
factor likely will be destroyed [27] and the
interaction of factor VIII with von Wille-
brand factor possibly is broken during bind-
ing of factor VIII to Sph6rosil PL. Andersson
and Brown [28] showed that this interaction
is broken when the complex binds to phos-
pholipid vesicles.
Remarkable is the frnding that the factor
IX assay is linear with the amount of factor
IX, even at nonsaturating amounts of factor
VIII. This means that under the described
conditions the fraction of factor IXu that is
bound in the factor X activating complex
fully depends on the factor VIII" concentra-
tion and is not dependent on the factor IX,
concentration. The factor VIII' concentra-
tion in the assay mixture is I U/ml which is
about 0.7 nM. The reaction rate is about
l0 nMlmin in case of the plasma with 1000/0
factor IX. Assuming a turnoyer rate of 851,
the factor X activating complex concentra-
tion is l2pM. This amount is only l.7o/o of
the total factor VIII. concentration, so the
change in free factor VIII" concentration by
doubling the factor IXu concentration (at
most) is only 1.70/o. These changes will not
have any measurable effect on the fraction of
factor IXu that will be bound, and thus the
assay will be linear over the whole range of
the assay. The plasma concentration of fac-
tor IX is about 60 nM, so the concentration
of factor IXu in the assay mixture is about
100 pM (fie.4). This means that only 120/o f
the factor IX" is bound in the complete fac-
tor X activating complex. In case of figure 5,
this percentage is even lower (about 2 0/o)
because of the high CaCl2 concentration.
It was shown that by increasing the CaCl2
concentration in the reaction mixture, the
formation of the complete factor X activat-
ing complex is inhibited. At a concentration
of 13.4 mM CaCl2, the activation of factor X
by factor IX" in the absence of factor VIII" is
almost optimal [7], and also activation of
factor IX by factor XIu probably is no1
slower than at 5 mM CaCl2129, 301. So the
inhibiting effect of a high concentration of
CaClz is only noticed when factor VIII. is
present. The mechanism of this inhibition
might be decreased binding of factor VIII. to
the complete factor X activating complex at
a higher CaCl2 concentration. This phenom-
enon requires further investigation, but this
falls outside the scope of this article.
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The frnding that increasing the CaCl2
concentration decreases the activity of the
complete factor X activating complex was
used to develop an assay suitable for clinical
use. Having present l3.4mM CaClz (final
concentration) in the reaction mixture, the
reaction is inhibited so much that it is not
necessary to dilute plasma 200-fold, but only
4l-fold. The plasma sample is diluted 41
times, so the final plasma dilution in the
reaction mixture is 369 times. This means
that clotting factors in the plasma are diluted
so that they do not affect the assay, whereas
inhibitors of activated clotting factors also
cannot have a detectable effect on the assay.
When plasma is used that is anticoagulated
with 3.8 0/0 sodium citrate, the citrate concen-
tration in plasma will be about 10 mM and
thus in the reaction mixture 0.027 mM. This
citrate will bind Ca ions, however, less than
0.20l0, so a detectable increase of the reaction
rate (because less Ca ions are present) cannot
be expected.
The lyophilization experiments have
shown that the reagents I and 2 can be
lyophilized without loss in activity. The ly-
ophilized reagents can be stored for at least a
few months without loosing their activity.
These results together with the stability tests
show that the assay is well suited for practi-
cal clinical use.
We have measured factor IX in different
types of plasma, namely normal pooled plas-
ma, factor IX defrcient plasma, plasmas with
a known percentage of factor IX (prepared
by mixing normal pooled plasma with factor
IX defrcient plasma), and plasmas of pa-
tients who were treated chronically with oral
anticoagulants. When we measured factor
IX in plasmas of known factor IX concentra-
tions, there was a good correlation between
the theoretical amount of factor IX and the
results found in the assay. The assay is not
sensitive for other factors than factor IX; for
that reason, the plasma dilution is not im-
portant. The signal is halved either when the
plasma is diluted twice or when it contains
500/o factor IX. Tran et al. [26] showed that
the correlation between the APTT-based as-
say and the chromogenic assay is very well.
In I case discrepancies were found, testing
plasmas from patients receiving oral antico-
agulants. The discrepancies were due to the
APTT-based test system. Tran et al. [26] also
showed that the amount of measured factor
IX was dependent on the plasma dilution in
case of the APTT test. The more the plasma
was diluted, the lower percentage factor IX
was detected in the plasma, whereas with the
chromogenic assay at every dilution, the
same percentage was found. At very high
plasma dilutions the APTT gives the same
result as the chromogenic assay.
We have found the same phenomenon
also. In table 2 this is illustrated: the more
the plasma is diluted, the lower percentage
factor IX is measured. Table 2 also shows
that the correlation is reasonable between
the chromogenic assay and the APTT-based
assay, provided that the plasma is suffi-
ciently diluted. The reason why the result of
the APTT-based assay depends on the
plasma dilution still has to be determined,
but this falls outside the goal of this article. It
might be related to the behavior of the decar-
boxylated clotting factors which possibly are
present in plasma of patients treated with
oral anticoagulants. These oral anticoagu-
lants (warfarin derivatives) inhibit the car-
boxylation (formation of y-carboxyglutamic
acid residues) of the vitamin K dependent
clotting factors (factors IX, X, VII, and II).
The decarboxylated clotting factors possibly
show some activity when their concentration
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is high (thus at a low plasma dilution), but at
lower concentrations they have no activity,
because they have a low affinity to phospho-
lipid membranes.
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